NETest IN THE NEWS


Professor Kjell Öberg and colleagues

Annals Onology 2020

NETest is an accurate diagnositc, prognostic, and predictor of neuroedocrine tumor disease


Propsective 565 patient/control study

Neuroendocrinology 2020

NETest >95% accurate for GEP-NETs & BP-NETs & predicts disease progression


New York State Department of Health Clinical Laboratory Permit PFI: 9138

License granted by NYDOH for New York State NETest patients


Predicting Response to PRRT

European Journal of Nuclear Medicine and Molecular Imaging 2018

An integration of 8 neuroendocrine specific genes and grade (PRRT Predictive Quotient) demonstrated to have clinical utility for predicting response to PRRT therapy in GEP- and BP- NETs


NETest®: A Non-Invasive, Test Service for Neuroendocrine Tumor Patients

  • NETest is the only non-invasive blood test that helps physicians identify the disease activity* of a neuroendocrine tumor.
  • Provides Healthcare Providers with quantifiable, objective, and reproducible test results.
  • Offers convenience as it only requires a routine blood draw.
  • We have studied thousands of bloods which have been used in the care of more than a 1,000 patients at multiple different medical centers.

The NETest is an In Vitro MultiAnalyte with Algorithm Analyses test service, performed in a single laboratory, assessing targeted gene expression profile of RNA isolated from peripheral blood. NETesting is intended to aid in the identification of active disease and therefore provide an assessment of treatment responses in neuroendocrine tumor patients at the time of testing in conjunction with standard clinical assessment. Indicated for use in patients: 21 years of age or older.

* Disease activity is defined here as the calculated risk of highly active disease as measured by an algorithm based on a combination of gene expression data and clinical parameters. NETest results are only to be used in conjunction with standard clinical assessment.

Your Questions Answered!

Irvin Modlin, MD, describes whether NETest replaces or supplements imaging
Dr. Modlin, Professor Emeritus, Yale School of Medicine, describes whether NETest replaces or supplements imaging
Irvin Modlin, MD, describes whether NETest replaces or supplements imaging

00:00:57
Views: 128
Irvin Modlin, MD, describes whether NETest replaces or supplements imaging

Irvin Modlin, MD, explains the reason NETest is more effective than a biomarker test such as CGA

00:00:55
Views: 203
Irvin Modlin, MD, explains the reason NETest is more effective than a biomarker test such as CGA

Irvin Modlin, MD, explains the specificity and sensitivity of the NETest

00:00:30
Views: 58
Irvin Modlin, MD, explains the specificity and sensitivity of the NETest

Irvin Modlin, MD, offers opinion of NETest and whether it is cost prohibitive

00:00:43
Views: 54
Irvin Modlin, MD, offers opinion of NETest and whether it is cost prohibitive

Irvin Modlin, MD, on when to use NETest clinically and situations it has clinical utility

00:00:42
Views: 74
Irvin Modlin, MD, on when to use NETest clinically and situations it has clinical utility

Irvin Modlin, MD, shares importance of NETest, requirement for testing, and where to send results

00:00:46
Views: 51
Irvin Modlin, MD, shares importance of NETest, requirement for testing, and where to send results